A Randomized Double Blind Clinical Trial to Evaluate the Effects of MK-7264 in Participants With Obstructive Sleep Apnea
Latest Information Update: 16 May 2022
At a glance
- Drugs Gefapixant (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 08 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Sep 2019 Planned End Date changed from 16 Dec 2019 to 22 Oct 2019.
- 30 Sep 2019 Planned primary completion date changed from 9 Dec 2019 to 22 Oct 2019.